| Species : |
Human |
| Source : |
E.coli |
| Tag : |
Non |
| Amino acid sequence : |
The sequence of the first five N-terminal amino acids was determined and was found to be Ala-Val-Pro-Ile-Gln. |
| Physical Appearance : |
White lyophilized (freeze-dried) powder. |
| Purity : |
Greater than 98.0% as determined by: (a) Gel filtration analysis. (b) Analysis by SDS-PAGE. |
| Formulation : |
The protein was lyophilized from a concentrated (1 mg/ml) solution with 0.0045 mM NaHCO3. |
| Solubility : |
It is recommended to reconstitute the Recombinant ly Human ophilized Leptin Antagonist Triple Mutant in sterile 0.4% NaHCO3adjusted to pH 8-9, not less than 100 µg/ml, which can then be further diluted to other aqueous solutions. |
| Biological Activity : |
Leptin triple antagonist is capable of inhibiting leptin-induced proliferation of BAF/3 cells stably transfected with the long form of human leptin receptor. It also inhibits various leptin effects in several in vitro bioassays. |
| Protein content : |
Protein quantitation was carried out by UV spectroscopy at 280 nm using the absorbency value of 0.88 as the extinction coefficient for a 0.1% (1mg/ml) solution at pH 8.0. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). |
| Storage : |
Recombinant Human Lyophilized Leptin Antagonist Triple Mutant although stable at room temperature for several weeks, should be stored desiccated below -18℃. Upon reconstitution at > 0.1 mg/ml and up to 2 mM and filter sterilization Leptin mutant can be stored at 4℃or even room temperature for several weeks making it suitable for long term infusion studies using osmotic pumps. At lower concentration addition of a carrier protein (0.1% HSA or BSA) is suggested. Please prevent freeze-thaw cycles. |
